Stuart A. Aaronson

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Stuart A. Aaronson, M.D.
Nci-vol-8199-300 Stuart Aaronson.jpg
Born(1942-02-28)February 28, 1942
Mount Clemens, Michigan
EducationUC Berkeley, UC SF
EmployerThe Mount Sinai Hospital
Known forCancer research
TitleJane B. and Jack R. Aron Professor of Neoplastic Diseases and Founding Chair Emeritus of Oncological Sciences

Stuart A. Aaronson, M.D. (born February 28, 1942) is an American author and internationally recognized cancer biologist.[1][2] He has authored more than 500 publications and holds over 50 patents, and was the Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences at The Mount Sinai Hospital in New York City until March 2013, when he assumed the title of Founding Chair Emeritus of the Department of Oncological Sciences.[3] The current Chairman of Oncological Sciences is Ramon E. Parsons.


Aaronson graduated summa cum laude from the University of California, Berkeley, in 1962, with a degree in chemistry. He earned his M.D. from the University of California, San Francisco Medical Center in 1966, and completed a fellowship at the University of Cambridge in England and an internship in medicine at Moffitt Hospital in San Francisco.[3]

In 1967, Aaronson joined the National Institutes of Health as a Senior Staff Fellow. He headed the Molecular Biology Section of the Viral Carcinogenesis Branch from 1970 until 1977, after which he became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, until 1993, when he was named Chairman of Oncological Sciences at The Mount Sinai Hospital.


Aaronson's early research established the transformation-competent but replication-defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes.[3][4] His investigations of the v-sis oncogene established the first normal function of an oncogene and its role in growth factor signaling.[1][2] His discovery of erbB2 as a v-erbB-related gene amplified in a human breast carcinoma and the demonstration of its transforming properties paved the way for targeted therapies directed against its product,[4] and his successful isolation of KGF (FGF7), a growth factor present in the epithelialization-phase of wound healing, led to Amgen's successful phase III clinical trial and FDA approval of KGF for treatment of mucositis.[5][6] Current research includes investigations into the mechanisms by which tumor suppressor genes induce permanent growth arrest/senescence, the signaling pathways involved, and investigations of the autocrine and paracrine acting growth factors PDGF, KGF, HGF, and Wnt ligands.[3]

Awards and honors[edit]

  • 1982 Rhoads Memorial Award
  • 1982 PHS Meritorious Service Medal
  • 1989 Paul Ehrlich Award
  • 1989 PHS Distinguished Service Medal
  • 1990 Milken Award
  • 1991 Chirone Prize
  • 1991 Harvey Lecture
  • 1991 Wadsworth Memorial Foundation Award
  • 2005 FLC Mid-Atlantic Regional Excellence in Technology Transfer Award – Kepivance
  • 2006 National FLC Award for Excellence in Technology Transfer – Kepivance: Improving the Quality of Life for Cancer Patients


Partial list:

Patent Number Title
6479255[7] Polynucleotides encoding human FRP and fragments thereof
6225088[8] DNA encoding plasminogen-like growth factor (PLGF) and related embodiments
6228600[9] Immunoassays for the alpha platelet-derived growth factor receptor
6403769[10] Fusion proteins that include antibody and nonantibody portions
6566098[11] DNA encoding truncated hepatocyte growth factor variants
6639060[12] erbB-3 nucleic acids
6653084[13] Anti-erbB-2 antibodies to human receptor related to but distinct from EGF receptor
6660488[14] Antibodies for the alpha platelet-derived growth factor receptor
6709842[15] DNA encoding a growth factor specific for epithelial cells
6833132[16] Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity


Partial list:


External links[edit]

Curr Biol. 2006 Dec 19;16(24):2466-72. RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. Ongusaha PP1, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW. Author information 1 Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA. 2019 retraction notice.

"Current Biology is retracting this paper, which reports that p53-mediated induction of RhoE in response to genotoxic stress promotes cell survival in part via inhibition of ROCK I-mediated apoptosis. Several years after publication of this work, two corrections to this paper were published in this journal in response to reader concerns regarding apparent duplication of western blots and irregularity of FACS plots in Figures 2 and 4 (; A review conducted by Harvard Medical School and Massachusetts General Hospital has now identified further issues involving data within Figure 2. In light of the cumulative issues, we have concluded that the most responsible course of action is therefore to retract the paper. The corresponding author, Sam W. Lee, does not agree with Current Biology’s decision to retract the paper."